Hemolytic transfusion reaction (HTR) is a serious complication that occurs during transfusion of blood or its components, which leads to the destruction (hemolysis) of the donor's red blood cells. This condition can manifest itself both acutely in the first hours after blood administration and delayed after several days. HTR is associated with immune-mediated reactions, when the recipient's antibodies attack the donor's red blood cells, not matching their group affiliation, or with non-immune factors. This reaction can lead to significant complications, including acute renal failure, shock, and even death of the patient. Thus, the main task of health workers is to recognize and promptly treat this syndrome, as well as prevent its occurrence at the stage of pre-transfusion preparation.
History of the disease and interesting historical facts
The history of hemolytic transfusion reactions begins with the discovery of blood groups by Austrian scientist Karl Landsteiner in the early 20th century. In 1901, he identified three main blood groups: A, B, and O, and later added group AB. This marked the beginning of safe transfusions, but blood group mismatch remains a major cause of GAD. Before the discovery of blood groups, hemolytic reactions were observed but could not be explained, and the incidence of such complications was much higher. In the 1940s, the discovery of Rh factors also improved transfusion safety. The history of GAD highlights the importance of careful matching of donor and recipient blood groups.
Epidemiology
The epidemiology of hemolytic transfusion reaction shows that this condition, despite progress in the field of medicine, continues to be a pressing problem. According to statistics, the frequency of hemolytic reactions is about 1 in 5000 transfusions, but this figure may vary in different clinics. Acute hemolytic reaction is more often observed in cases where transfusion is performed with insufficient preparation or in emergency situations. In particular, the global incidence of such reactions in developed countries is about 0.02% of the total number of transfusions, while in developing countries these figures can reach 1%. Effective work on training donors and medical personnel significantly reduces the level of such complications.
Genetic predisposition to this disease
Hemolytic transfusion reactions have a specific genetic basis associated with polymorphisms in genes responsible for the immune response. For example, genes encoding proteins of the ABO and Rh blood systems play a key role in the development of these reactions. People with certain genetic markers, such as HLA-DRB1, have a significantly increased risk of developing hemolytic reactions. Research suggests that polymorphisms in genes regulating the immune response may predispose to more aggressive transfusion reactions. However, it is important to note that genetic predisposition is only one of many factors that contribute to the development of GAD.
Risk factors for the development of this disease
The risk of developing a hemolytic transfusion reaction may be increased by a variety of factors, both physical and chemical. These include:
- Blood group mismatch (ABO, Rh factor);
- Existing autoimmune diseases;
- Previous transfusions, especially if they were unsuccessful;
- Increased blood viscosity (eg, during dehydration).
Other risk factors include the patient's medical condition (particularly the presence of immunodeficiencies or previous severe illnesses) and the possibility of the presence of antigens on the donor's red blood cells that may cause a reaction in an individual recipient.
Diagnosis of this disease
Diagnosis of hemolytic transfusion reaction involves a variety of methods, including clinical evaluation and laboratory testing. The main symptoms of GAD may include:
- Fever;
- Dyspnea;
- Lower back pain;
- Significant increase in the level of bilirubin in the blood;
- Increased lactate dehydrogenase (LDH) levels;
Laboratory tests typically include:
- Determination of blood group;
- Testing for the presence of specific antibodies;
- Determination of hemoglobin and hematocrit levels;
Radiological investigations may include ultrasound and CT scans if necessary to exclude other causes of deterioration of the patient's condition. It is also important to perform a differential diagnosis to exclude other causes of hemolysis.
Treatment
Treatment of hemolytic transfusion reaction requires immediate intervention. The main goals of therapy include removal of the antigen and restoration of circulating blood volume. Primary treatment involves stopping the transfusion, monitoring the patient's vital signs, and providing supportive care. Pharmacological treatment may include:
- Corticosteroids to reduce the inflammatory response;
- Antihistamines to reduce the symptoms of an allergic reaction;
- Crystalloid infusions to replenish circulating blood volume.
In more severe cases, surgical treatment may be required, such as hemodialysis for kidney failure. Other possible treatment options may include plasmapheresis to remove antibodies from the bloodstream.
List of medications used to treat this disease
The main drugs used in hemolytic transfusion reactions include:
- Methylprednisolone;
- Dexamethasone;
- Dipenhydramine (Benadryl);
- Hydroxyethyl starch;
- Polydextrose ions.
The choice of a specific drug depends on the type and severity of the reaction, as well as the individual characteristics of each patient.
Disease monitoring
Monitoring the patient's condition in hemolytic transfusion reaction is a critical step in medical intervention. Control steps include regular blood tests for hemoglobin, hematocrit, bilirubin, and other indicators. The prognosis with timely intervention is favorable in most cases. However, complications such as acute renal failure, thrombocytopenia, and failure of other organs are possible, which requires additional monitoring and care.
Age-related features of the disease
Hemolytic transfusion reactions may occur differently depending on the age of the patient. Newborns and young children may be at increased risk of developing reactions due to their immune system. Older patients may generally have a less severe reaction, but there is a high risk of serious complications. In adults, reactions are usually due to previous illnesses or recent vaccinations.
Questions and Answers
- How quickly can symptoms of a hemolytic transfusion reaction appear? Symptoms may develop within minutes to hours after the transfusion.
- Is it possible to predict who will be susceptible to a hemolytic reaction? Yes, patients with known allergies or previous transfusion reactions are at increased risk.
- What are the main measures to prevent GAD? The main measure is careful matching of the blood groups of the donor and recipient, as well as continuous training of medical personnel.
- What is the risk of death from hemolytic reactions? Fatal outcomes with adequate treatment occur in 1-3% cases of acute hemolytic reactions.
- How is hemolytic transfusion reaction treated? Treatment includes stopping the transfusion, using corticosteroids, antihistamines, and providing life support to the patient.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov advises that if you suspect a hemolytic transfusion reaction, you should immediately notify medical personnel. “Hemolysis can be life-threatening,” he emphasizes. It is also important to monitor for symptoms after a transfusion, such as fever or shortness of breath. “If you know you have specific antibodies, notify your doctor before the procedure,” the doctor adds. In the event of a severe transfusion reaction, it is important to ensure access to high-quality medical care.
